Avicanna Publishes First Real-World Evidence Study on Medical Cannabis for Chronic Pain Management
Key Insights
Avicanna announced publication of results from a prospective observational study evaluating physician-supervised medical cannabis use in chronic pain (search) patients over 24 weeks.
The study demonstrated statistically significant improvements in pain interference, pain intensity, anxiety (search), depression (search), and quality of life measures among patients who remained on treatment.
While improvements did not meet minimal clinically important difference thresholds, the findings support medical cannabis potential in selected patients under healthcare provider supervision.
Avicanna Inc. (search) has announced the publication of results from its first peer-reviewed Medical Cannabis Real-World Evidence (MCRWE) study in the Canadian Journal of Pain, marking a significant milestone in evidence-based cannabinoid medicine research. The investigator-led study, conducted through Avicanna's MyMedi.ca platform, evaluated patient-reported outcomes among chronic pain (search) patients receiving physician-authorized medical cannabis in routine clinical practice.
Study Design and Methodology
The prospective, observational study was led by Dr. Hance Clarke, Director of Pain Services at University Health Network (UHN), with support from multiple clinicians and medical institutions across Canada. The research followed a cohort of chronic pain (search) patients over a 24-week follow-up period, using validated assessment tools commonly employed in pain and mental health research.
"While the term 'medical cannabis' is widely used, this study specifically evaluated outcomes among patients using medical cannabis under the supervision of a health-care provider," said Dr. Hance Clarke, Principal Investigator and Clinician at UHN. "Among chronic pain (search) patients who remained on an authorized medical cannabis product at six months, improvements were observed in pain severity, pain interference, and several health-related outcomes."
Clinical Outcomes and Statistical Significance
The observational results demonstrated statistically significant improvements from baseline across multiple validated measures. Patients showed improvements in pain interference and pain intensity, as well as validated measures of anxiety (search), depressive symptoms, and overall quality of life over the 24-week observation period.
However, the study noted important limitations in the clinical significance of these findings. While the magnitude of change did not meet established minimal clinically important difference thresholds, the observed directional improvements align with findings reported in existing real-world and clinical literature. The results underscore the need for further placebo-controlled randomized trials to better define optimal dosing strategies, formulations, and routes of administration for medical cannabis.
Scientific Platform and Regulatory Implications
"This first peer-reviewed publication from our real-world evidence platform represents an important milestone," said Karolina Urban, PhD, Executive Vice President of Scientific and Medical Affairs at Avicanna. "High-quality, prospective real-world data can play a critical role in complementing randomized clinical trials, informing clinical practice, and supporting the responsible integration of cannabinoid-based medicines into evidence-based care."
Urban emphasized the growing importance of physician-supervised models and rigorous data generation as regulatory frameworks evolve globally. The study reflects a healthcare provider-supervised model of medical cannabis use, highlighting the importance of clinician involvement in monitoring efficacy, safety, and ongoing patient outcomes.
Ongoing Research and Expansion
The MCRWE study continues with ongoing patient recruitment under Dr. Clarke's leadership. Participants have been enrolled across seven Canadian provinces, with support from multiple medical institutions. The study is designed to evaluate patient-reported outcomes associated with medical cannabis use, including pain, sleep, anxiety (search), depression (search), and epilepsy (search), using validated assessment tools over a 24-week follow-up period.
Secondary objectives include the assessment of changes in concomitant medication use. Avicanna provided patient support services and clinical and data infrastructure required for large-scale real-world evidence research, while its scientific and medical teams supported platform operations, education, and data coordination without influencing clinical decision-making or patient care.
Commercial Platform Integration
The study was implemented through Avicanna's MyMedi.ca platform, a medical cannabis care platform operated by Northern Green Canada Inc. (search) The platform features a diverse portfolio of products and bilingual pharmacist-led patient support programs, providing specialty services to distinct patient groups such as veterans and collaborating with public and private payers for adjudication and reimbursement.
Avicanna has established four commercial-stage business pillars, including its RHO Phyto medical cannabis formulary offering oral, sublingual, topical, and transdermal delivery systems with varying cannabinoid ratios. The company has also developed a pharmaceutical pipeline of proprietary, indication-specific cannabinoid-based candidates in various stages of clinical development, targeting unmet needs in dermatology, chronic pain (search), and neurological disorders.